Immunofoco
Latest round
- Series B
Last raised
- Dec 2025
Total raised
- $45M
Investors
- 14
About Immunofoco
, dba Immunofoco, is a clinical-stage biotech company that focuses on immune cell therapies for solid tumors. The company has developed multiple platforms including Peri Cruiser, SNR, T-Booster, and HTS.S.S. In 2023 and 2024, additional candidates such as IMC001 (EpCAM CAR-T) and IMC008 (SNR CAR-T) also received FDA ODD designations. Immunofoco has been recognized among China’s top potential unicorn enterprises and awarded several honors from national biopharmaceutical association. The company adopts immune cell therapy technology platforms to develop solid tumor therapeutics. Its product includes CAR-T products for solid tumors, including IMC001, IMC002 and IMC008. The company developed Peri Cruiser® technology platform which was designed to reduce the on-target, off-tumor (OTOT) toxicity in solid tumors. The company generates revenue from developing immune cell therapy drugs.
Who invested in Immunofoco
14 investors across 5 rounds
See all investors in Immunofoco
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Immunofoco
Who invested in Immunofoco?
Immunofoco has 14 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Immunofoco raised?
Immunofoco has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Immunofoco last raise money?
Immunofoco's most recent round on record is a Series B, in Dec 2025.
What does Immunofoco do?
, dba Immunofoco, is a clinical-stage biotech company that focuses on immune cell therapies for solid tumors.
Where is Immunofoco headquartered?
Immunofoco is headquartered in Shanghai, China.
Which VCs invest in companies like Immunofoco?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Immunofoco's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Immunofoco? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.